Half Yearly Report and Accounts
February 21 2019
Read moreJanuary 18 2019
PolyNovo is pleased to announce the successful registration of NovoSorb BTM with the Medical Device Authority of Malaysia. This regulatory approval is the first of several Asian regulatory registrations anticipated.
January 18 2019
PolyNovo wishes to announce the purchase of an adjoining office/warehouse facility. The intention is to combine the facilities and buildings allowing an expanded production facility suitable for several years.
December 12 2018
PolyNovo is pleased to announce the appointment of Mr Jan-Marcel Gielen as Chief Financial Officer and Company Secretary efffective 12 December.
Read more
November 1 2018
PolyNovo is pleased to announce regulatory approval for the sale of NovoSorb BTM (NovoDerm) in India and the signing of Myovatec Surgical Systems Pvt Ltd (Myovatec) as its distributor.
October 9 2018
PolyNovo was recently featured on the National evening news. Please click to see the news story.
Read more
August 14 2018
PolyNovo is pleased to announce that the NovoSorb BTM device is now entered in the TGA ARTG (Australian Register for Therapeutic Goods) following Conformity Assessment review via the Priority Review Designation pathway.
August 2 2018
PolyNovo is pleased to announce that the last patient has been enrolled in the NovoSorb® Biodegradable Temporising Matrix (BTM) Full Thickness Burn feasibility clinical trial being conducted in the USA.
July 28 2018
PolyNovo is pleased to announce regulatory approval for NovoSorb BTM to be sold in Saudi Arabia and the signing of Al Mofadaly as its exclusive distributor.
July 26 2018
The Melbourne company PolyNovo Ltd has offered its life changing product for the use on burns victims in Greece. The company's NovoSorb® BTM has been offered to the surgical teams caring for patients burnt in the fires.
May 22 2018
PolyNovo is pleased to announce that the last patient has been enrolled in the NovoSorb BTM Full Thickness Burn clinical trial.
Read moreApril 18 2018
PolyNovo congratulates Prof John Greenwood and Dr Marcus Wagstaff on winning “Best in Category- Wounds” for their Poster at the American Burn Association (ABA) meeting in Chicago.
April 3 2018
PolyNovo Ltd is pleased to announce the signing of the project plan for the development of a range of breast products with Establishment Labs (EL).
Read more
March 20 2018
PolyNovo has been featured in the quarterly journal, the Australian Business Executive. A printed journal can be obtained through TheABE.com.au website/ subscription.
February 1 2018
PolyNovo is delighted to announce four clinical presentations related to the use of NovoSorb® BTM by US surgeons at the 40th Boswick Burn and Wound Symposium.
Read moreJanuary 23 2018
PolyNovo Ltd is pleased to announce the appointment of Greg Lewis to a new combined role of COO, CFO and Company Secretary.
Read more
January 17 2018
PolyNovo Ltd is pleased to announce the signing of a heads of agreement with Establishment Labs, a global medical device company focused on breast aesthetics and reconstruction technologies.
Read more
December 14 2017
PolyNovo Ltd is pleased to release the presentation to be given by CEO Paul Brennan and Chairman David Williams to Hong Kong institutional investors today.
Read moreNovember 29 2017
PolyNovo Ltd is pleased to release the interview and presentation given by CEO Paul Brennan yesterday (28 Nov) at the Financial News Network (FNN) in Melbourne.
Read moreNovember 21 2017
PolyNovo Ltd is pleased to release the presentation to be given by CEO Paul Brennan today at the Financial News Network (FNN) CEP Sessions in Melbourne.
Read moreOctober 27 2017
PolyNovo Limited advises that its Share Purchase Plan has closed. The Company is delighted with the response to the SPP offer resulting in applications for 59.4 million new shares and raising $16.0 million.
Read moreOctober 20 2017
Ms Andrea Goldie has resigned as Company Secretary effective 18 October 2017.
Read moreOctober 15 2017
PolyNovo is delighted to announce the signing of a Memorandum of Understanding (MOU) with an innovative global medical device company for the development of a range of breast devices based on the NovoSorb polymer technology.
Read moreOctober 4 2017
PolyNovo is pleased to announce the signing of AMI Medical Technologies Ltd (AMI) as its distributor for the company’s NovoSorb™ BTM (Biodegradable Temporising Matrix) in Israel.
Read moreSeptember 26 2017
We are pleased to announce we have successfully completed a placement to professional and sophisticated investors to raise $7 million at $0.27 per share.
Read moreSeptember 1 2017
PolyNovo is delighted to announce the first sales of NovoSorb BTM to one of the major hospitals in the US.
Read moreJune 1 2017
PolyNovo is pleased to announce that the Royal College of Surgeons (UK) have published Professor John Greenwood’s 2016 Hunterian Lecture. This paper outlines the evolution of burn care and the potential shift in patient care through the development of NovoSorb BTM (Biodegradable Temporizing Matrix).
May 12 2017
PolyNovo has been collaborating with Beta Cell Technologies Pty Ltd (“Beta Cell”) from Adelaide on a research project exploring the potential of integrated NovoSorb™ BTM to host pancreatic islets in the skin.
April 11 2017
PolyNovo Limited is pleased to release the presentation to be given by CEO Paul Brennan today at the ASX CEO Sessions in Sydney.
February 22 2017
PolyNovo Limited (“PolyNovo”) is pleased to announce the first US patient has been treated with our Biodegradable Temporising Matrix (BTM).
Read moreFebruary 21 2017
PolyNovo Limited (“PolyNovo”) is pleased to announce our first Biodegradable Temporising Matrix (BTM) order in South Africa.
Read more
December 8 2016
Tony Lowther MD of Ascendis Medical attended the PolyNovo office for the signing of the agreement. It is great to have Tony and his Team working with PolyNovo.
Read more
December 2 2016
PolyNovo is pleased to announce the appointment of Owens and Minor (O&M) as its strategic logistics partner (3PL) in the United States (US).
Read more
October 10 2016
PolyNovo & Device Technologies distribution agreement.
Read more
October 3 2016
PolyNovo announces the direct market entry into the US market with our own sales team.
Read more
August 16 2016
New Branding/Logo reflecting our move towards a commercial enterprise.
Read more
July 29 2016
This Adelaide newspaper article outlines how the technologies may address some aspects of diabetes treatments in the future.
Read more
July 27 2016
Adelaide Ch:10 TV article on the BTM use in Diabetes research.
Read more
June 14 2016
PolyNovo is pleased to be a silver sponsor of the 2017 ANZBA (Burns) Conference being held in Adelaide in October 2017.
Read more
May 31 2016
ASX Announcement of the start of the BARDA funded feasibility trials in US.
Read more
May 3 2016
A newsletter write up of PolyNovo and the changes in focus over the past 18 months.
Read more
May 3 2016
ASX Announcement of the start of the BARDA funded feasibility trials in US.
Read moreApril 30 2016
This is the synchronized slide presentation from the ASX/FNN CEO Sessions in Melbourne 19 April.
Read more
February 1 2016
PNV is a Melbourne based medical device company that designs and manufactures solutions for its NovoSorb biodegradable polymer technology.
Read more
February 1 2016
PNV is a Melbourne based medical device company that designs and manufactures solutions for its NovoSorb biodegradable polymer technology.
Read more